A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial
Mike Dennis, Alan Burnett, Robert Hills, Ian Thomas, Cono Ariti, Marianne T Severinsen, Claire Hemmaway, Paul Greaves, Richard E Clark, Mhairi Copland, Nigel Russell, National Cancer Research Institute (NCRI) acute myeloid leukaemia (AML) Working Group, Peter Kampmann (Medlem af forfattergruppering), Jindrich Mourek (Medlem af forfattergruppering), Lars Kjeldsen (Medlem af forfattergruppering), Ove Juul Nielsen (Medlem af forfattergruppering), Carsten Utoft Niemann (Medlem af forfattergruppering)
Dyk ned i forskningsemnerne om 'A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial'. Sammen danner de et unikt fingeraftryk.